PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE.

Phase 3

• Conditions: LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE UCNT

• Registration Number: NCT00180973
• Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Brief Summary

MULTICENTRIC INTERNATIONAL RANDOMIZED PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY (BEC REGIMEN) FOLLOWED BY STANDARD RADIOTHERAPY (70 Gy / 7 WEEKS) VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE (UCNT).

Detailed Description

Not available

Study Timeline

• Study Start: 1995-02
• Status Verified: 2005-09
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Last Update Submitted: 2005-09-13
• Study First Posted: 2005-09-16
• Last Update Posted: 2005-09-16

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 520

Inclusion Criteria

• of either sex
• aged *15 and * 70 years
• never previously treated with radiotherapy, chemotherapy or surgery for malignant disease (except neck adenectomy/diagnosis)
• with aWHO performance status * 2.
• amenable to regular follow-up
• capable of receiving chemotherapy and radiotherapy : in particular, with no contraindications to the use of anthracyclines, bleomycin or cisplatinum.
• with informed consent at entry time, in writing or witnessed oral informed consent, in accordance with local legislation requirements.
• Laboratory requirement : *Baseline hematologic status :

Neutrophil count * 2000 /mm3 Platelet count * 150,000 /mm3 Hemoglobin * 10 g / dl

Read More

Exclusion Criteria

• Histologic types other than type II - III of the WHO classification
• T1 - T2 N0 - N1 or patients with metastatic
• Aged < 15 or > 70.
• Patients in whom chemotherapy is contraindicated: history of myocardial infarction over the last 6 months before inclusion, or clinically present cardiac pathology.
• WHO Performance status >2
• History of prior malignancies (other than non melanoma skin cancer or excised cervical carcinoma in situ).
• Uncontrolled infection,
• Patients refusing participation.
• Patients who, for social, familial or geographic reasons are unlikely to comply with a long term follow-up.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
5 year overall survival rate

Secondary Outcome Measures

Name	Time	Method
Time to progresion and local control at 2 years

Trial Locations

Locations (1)

Institut Gustave Roussy; 🇫🇷 Villejuif, France